Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.

doi:10.1016/j.jtho.2026.103565

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2026

Mankuzhy Nikhil P, Santo Valentina, Shin Jacob Y, Chaunzwa Tafadzwa L, Gelblum Daphna Y, Wu Abraham J, McMillan Matthew T, Ma Jennifer, Billing David, Iyengar Puneeth, Simone Charles B, Offin Michael, Schoenfeld Adam J, Arbour Kathryn C, Alessi Joao, Pecci Federica, Garbo Edoardo, Gariazzo Eleonora, Awad Mark M, Gomez Daniel R, Chaft Jamie E, Ricciuti Biagio, Shaverdian Narek

Abstract excerpt

INTRODUCTION: Outcomes in unresected locally advanced NSCLC (LA-NSCLC) are poor despite improvement with immunotherapy after concurrent chemoradiation (cCRT). Although KRAS is the most common mutated oncogene in NSCLC, its impact on outcomes in LA-NSCLC treated with cCRT and durvalumab remains underexplored. METHODS: We conducted a multicenter retrospective analysis of patients with stage III nonsquamous NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemoradiotherapy

Share to Immunotherapy

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 41619904
DOI: 10.1016/j.jtho.2026.103565

Genes

KRAS
CDKN2A
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.PMID 41619904Read ↗

Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survivalSemantic proximity Read ↗

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung CancerSemantic proximity Read ↗

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival.Semantic proximity Read ↗

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.Semantic proximity Read ↗

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery.Semantic proximity Read ↗

Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective AnalysisSemantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.